Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 36,800 shares, an increase of 1,500.0% from the December 31st total of 2,300 shares. Based on an average daily volume of 214,500 shares, the short-interest ratio is currently 0.2 days.

Chugai Pharmaceutical Stock Down 0.8 %

Shares of CHGCY traded down $0.17 during trading hours on Tuesday, reaching $20.76. 251,326 shares of the company traded hands, compared to its average volume of 189,677. The stock has a market capitalization of $68.32 billion, a P/E ratio of 26.62 and a beta of 0.81. Chugai Pharmaceutical has a 12-month low of $14.52 and a 12-month high of $26.00. The business has a fifty day moving average price of $21.62 and a 200-day moving average price of $22.44.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Friday, October 25th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $2.12 billion for the quarter. Chugai Pharmaceutical had a net margin of 33.85% and a return on equity of 22.30%. As a group, research analysts predict that Chugai Pharmaceutical will post 0.78 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.